key: cord-0714938-lzgf85yz authors: Hansen, Cecilie Bo; Jarlhelt, Ida; Hasselbalch, Rasmus Bo; Hamm, Sebastian Rask; Fogh, Kamille; Pries‐Heje, Mia Marie; Møller, Dina Leth; Heftdal, Line Dam; Pérez‐Alós, Laura; Sørensen, Erik; Larsen, Margit Anita Hørup; Skjoedt, Mikkel‐Ole; Ostrowski, Sisse Rye; Frikke‐Schmidt, Ruth; Bayarri‐Olmos, Rafael; Hilsted, Linda Maria; Bundgaard, Henning; Nielsen, Susanne Dam; Iversen, Kasper Karmark; Garred, Peter title: Antibody‐dependent neutralizing capacity of the SARS‐CoV‐2 vaccine BNT162b2 with and without previous COVID‐19 priming date: 2021-08-02 journal: J Intern Med DOI: 10.1111/joim.13366 sha: 58884397bdcc085600a32de10a7c7509e8f95776 doc_id: 714938 cord_uid: lzgf85yz nan We report data on the antibody response against the SARS-CoV-2 receptor-binding domain (RBD) in healthcare professionals from two hospitals in Copenhagen at baseline and 3 weeks post the first injection with the BNT162b2 mRNA COVID-19 vaccine. The response was assessed using assays measuring antibody neutralizing capacity (NAbs) [1] and direct binding of IgG, IgM and IgA [2] . Moreover, we tested antibody responses against the nucleocapsid (N) protein, which is not a part of the vaccine and used as a proxy for natural infection. For details, see the Supporting Information. Out of the 1460 participants, 1227 were females (Supporting Information Table S1 ). The included subjects were categorized as SARS-CoV-2 primed with a natural infection if they were positive at day 0 (baseline). At baseline, 108 participants (7.4%) and approximately 3 weeks after the first vaccination, 122 participants (8.3%) were N protein seropositive, respectively (Fisher's exact test, p < 0.0001). A total of 65 of the 108 (60.2%) seropositive patients had received reverse transcription polymerase chain reaction (RT-PCR) laboratory confirmation of SARS-CoV-2 infection before inclusion in the study. Divided according to age, seropositivity at baseline showed that the prevalence was highest among the participants below 30 years of age (17.3%) and decreased (3.9%) in those 60 years of age and above (Supporting Information Table S1 ; X 2 , p < 0.0001). Thirty participants (2.1%) remained IgG RBD seronegative after 3 weeks. In individuals with a previous SARS-CoV-2 infection compared with infection naïve, the vaccine responses were significantly increased for both NAbs, IgG, IgA and IgM (Mann-Whitney U test, p < 0.0001, p < 0.0001, p < 0.0001 and p = 0.0001, respectively; Fig. 1a -d). Among previously SARS-CoV-2 infected individuals, 98.4% were positive for NAbs compared with 75.8% in the infection naïve group 3 weeks postvaccination (Mann-Whitney U test, p < 0.0001) (Fig. 1a) . The vaccine antibody responses decreased gradually by increasing age (Kruskal-Wallis test, p < 0.0001) (Fig. 1e ,f). Females had a higher neutralizing and IgG antibody vaccine response than males (Mann-Whitney U test, p = 0.0017 and 0.0085, respectively; Fig. 1g ,h). No significant difference in vaccine responses was reflected in body mass index (BMI) nor in the time since the positive PCR test (Supporting Information Figs S1 and S2). Multiple regression analysis (Supporting Information Table S2 ) revealed that with increasing age, the IgG antibody response after the first vaccination declined significantly compared to the youngest age group (<30 years). Previous SARS-CoV-2 infection was associated with the most pronounced IgG antibody response (p < 0.0001). Male sex was associated with a lower IgG antibody response in all regression models (p = 0.0002, p < 0.0001 and p = 0.001). Furthermore, when dividing the participants into BMI groups we found no significant association to IgG antibody responses (p > 0.05). This study shows that a single dose of the BNT162b2 vaccine induces a robust antibody response in individuals that have experienced previous COVID-19 infection. This is compatible with a recent observation that prior infection equals a double vaccine dose of the BNT162b2 [3] . In general, low responsiveness to vaccines increases with age, and our observation that the antibody responses to the BNT162b2 vaccine decrease by each centile are compatible with this knowledge [4] . Furthermore, sex appeared to play a significant but less pronounced role since females mounted a significantly higher antibody response, which has been reported previously regarding other viral vaccines [5] . Fourteen individuals (1.1%) became N proteinpositive during the 3-week observation period, indicating that they had contracted COVID-19 after the first injection. This agrees with initial findings in the BNT162b2 phase three trial that there is a lag phase of around 10 to 14 days before a robust protective response is generated [6] . Thirty individuals (2.1%) of the vaccinated participants did not generate any vaccine antibody response against RBD. These individuals were also negative for N protein responses. Our results are in line with previous observations that about 2-10% of healthy individuals fail to mount antibody responses to routine vaccines [7] . However, it might be possible that some individuals may need a second booster to mount a detectable immunological response. Obese individuals may have increased susceptibility to infections [7] , and for some vaccines elevated BMI is associated with poor vaccine responsiveness [8, 9] . We did not find an association of vaccine responses with BMI in this cohort. However, this should be interpreted with some caution. The median BMI in our study was 23.9 and 90% of the included subjects had a BMI below 30 and were thus not obese. Therefore, our study might have been underpowered to detect an effect of obesity. We conclude that age and sex appear to be significant factors in how well a vaccine response is mounted. Previous natural SARS-CoV-2 infection is associated with a more rapid and robust response to a COVID-19 vaccine than individuals who were not infected. SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptorbinding domain SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 Immunosenescence and vaccine failure in the elderly The Xs and Y of immune responses to viral vaccines Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Primary vaccine failure to routine vaccines: why and what to do? Impaired immunogenicity of hepatitis B vaccine in obese persons Obesity is associated with impaired immune response to influenza vaccination in humans Department of Clinical Immunology, Section 7631, Laboratory of Molecular Medicine